



NEWS RELEASE for April 11, 2007

BIOLASE ANNOUNCES PRELIMINARY FIRST QUARTER RESULTS

IRVINE, CA (April 11, 2007)...BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today that, based on a preliminary review of its financial performance, the Company expects to report net revenue in the range of \$14.5 million to \$15.0 million and a net loss for the first quarter ended March 31, 2007.

President and CEO Jeffrey W. Jones commented, "While there is typically a sizable decline in revenues between the fourth and first quarters, we had anticipated greater results in this year's first quarter than we actually obtained. During the quarter, we worked hard to ensure the future effectiveness of our North American distribution arrangement with Henry Schein by having our sales representatives take time from selling activities in order to build relationships with and educate the Schein representatives in their territories. We believe that this investment today is crucial in order to ensure great success in the future from our relationship with Schein. Also, we believe that this first quarter just ended will be our lowest revenue quarter in 2007 and that we have not lost market share to our competitors, as we remain by a wide margin the market leader."

"We continue to be excited about the laser technology products available from Biolase, and look forward to a successful and long-lasting relationship, as we bring these products to the dental market," said James Breslawski, President and Chief Operating Officer, Henry Schein, Inc.

Mr. Jones added, "I'm happy to report that we experienced strong order volume for our new *ezlase*[™] soft tissue diode laser system during the quarter. We began shipping *ezlase* units to customers at the very end of March, but it was too late in the quarter to have a significant beneficial effect on Q1 revenues. In addition to the *ezlase* launch, we have made excellent progress in a comprehensive development program we believe will generate new revenue streams and increased revenue from consumables, with implementation and revenues beginning this year. We are committed and focused on building the Company for the long term, and we remain confident that our efforts to date will yield a solid 2007 with significant revenue growth."

The Company will provide additional details on a quarterly conference call and webcast following its first quarter 2007 operating results report in early May.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (<http://www.biolase.com>), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations including, but not limited to, management's assessment of its competitive position and its expectation of adding new revenue streams and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein. These risks are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance, therefore, should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

For further information, please contact: Jeffrey W. Jones, President & CEO; Richard L. Harrison, Executive Vice President and CFO of BIOLASE Technology, Inc., +1-949-361-1200; or Jill Bertotti, of Allen & Caron, +1-949-474-4300.